We are live on ! Find out more
VM

VHCP Management Portfolio holdings

AUM $93M
1-Year Est. Return 10.04%
This Fund
S&P 500
This Quarter Est. Return
+6.45%
1 Year Est. Return
-10.04%
3 Year Est. Return
+233.99%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$135M
AUM Growth
–
Cap. Flow
+$137M
Cap. Flow %
102.07%
Top 10 Hldgs %
86.88%
Holding
17
New
17
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$26M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$24.1M
3
KERX
Keryx Biopharmaceuticals Inc
KERX
+$16M
4
DYAX
DYAX CORPORATION
DYAX
+$13.6M
5
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$9.75M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 72.88%
2 Miscellaneous 27.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
1
Neurocrine Biosciences
NBIX
$15.8B
$26.3M 19.52%
+1,964,673
New +$24.1M
IRWD icon
2
Ironwood Pharmaceuticals
IRWD
$701M
$17.9M 13.27%
+2,149,200
New +$26M
KERX
3
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$15.3M 11.37%
+2,048,773
New +$16M
DYAX
4
DELISTED
DYAX CORPORATION
DYAX
$14.4M 10.68%
+4,156,508
New +$13.6M
ANAC
5
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$9.01M 6.69%
+1,610,856
New +$9.75M
TSRO
6
DELISTED
TESARO, Inc.
TSRO
$8.55M 6.35%
+261,130
New +$8.07M
GWPH
7
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$7.38M 5.48%
+837,800
New +$7.42M
VNDA icon
8
Vanda Pharmaceuticals
VNDA
$329M
$6.36M 4.73%
+787,459
New +$5.3M
ALBO
9
DELISTED
Albireo Pharma Inc
ALBO
$6.05M 4.49%
+48,214
New +$5.02M
CHTP
10
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
$5.79M 4.3%
+2,516,870
New +$5.09M
HPTX
11
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$5.61M 4.17%
+255,000
New +$5.58M
MTEM
12
DELISTED
Molecular Templates, Inc.
MTEM
$3.6M 2.67%
+4,145
New +$3.5M
ONCT
13
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$3.3M 2.45%
+357
New +$2.75M
ALXA
14
DELISTED
Alexza Pharmaceuticals Inc
ALXA
$1.74M 1.29%
+399,999
New +$1.81M
BCRX icon
15
BioCryst Pharmaceuticals
BCRX
$2.52B
$1.57M 1.17%
+1,013,442
New +$1.75M
STML
16
DELISTED
Stemline Therapeutics, Inc.
STML
$1.19M 0.89%
+50,000
New +$796K
ANTH
17
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$666K 0.49%
+22,463
New +$838K

Similar funds

QGI
Quadrangle GP Investors New York $93.6M AUM 10.64% 1-Year Est. Return
KC
Kanha Capital New York $89.9M AUM
RSCM
Rail-Splitter Capital Management Chicago, Illinois $89.4M AUM 15.13% 1-Year Est. Return
ZC
Zelman Capital Beachwood, Ohio $81.9M AUM 22.32% 1-Year Est. Return
TF
Trutina Financial Bellevue, Washington $76.7M AUM 19.34% 1-Year Est. Return
SAM
Sunnymeath Asset Management Red Bank, New Jersey $71.2M AUM 26.57% 1-Year Est. Return
NA
NS Advisors Westport, Connecticut $71M AUM 25.21% 1-Year Est. Return
NCIM
New Century Investment Management Southfield, Michigan $70.5M AUM 23.2% 1-Year Est. Return

VHCP Management's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for VHCP Management, which disclosed 17 positions worth $135M. Its ten largest holdings account for 87% of the portfolio.

Its largest position is Ironwood Pharmaceuticals: 2,149,200 shares worth $17.9M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, followed by Miscellaneous.

  • VHCP Management's largest Q2 2013 buy was Ironwood Pharmaceuticals: 2,149,200 shares worth $17.9M.
  • VHCP Management's ten largest holdings make up 87% of its $135M portfolio in Q2 2013.
  • VHCP Management disclosed 17 positions in Q2 2013, its first 13F filing on record.

Based on VHCP Management's 13F filing for Q2 2013, filed 14 Aug 2013.